SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-172960
Filing Date
2022-06-13
Accepted
2022-06-13 16:34:03
Documents
12
Period of Report
2022-06-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d366008d8k.htm   iXBRL 8-K 32777
  Complete submission text file 0001193125-22-172960.txt   160401

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA verv-20220609.xsd EX-101.SCH 2858
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20220609_lab.xml EX-101.LAB 18739
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20220609_pre.xml EX-101.PRE 11709
6 EXTRACTED XBRL INSTANCE DOCUMENT d366008d8k_htm.xml XML 3473
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 221012092
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences